Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 2
1988 1
1989 1
1990 1
1991 2
1992 2
1993 1
1994 2
1995 1
1996 1
1998 1
1999 1
2000 2
2002 1
2005 1
2006 3
2007 4
2008 1
2009 6
2010 1
2011 5
2012 6
2013 3
2014 4
2015 4
2016 3
2017 1
2018 2
2019 3
2020 2
2021 2
2022 3
2023 2
2024 3
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.
Elez E, Yoshino T, Shen L, Lonardi S, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Morris VK, Wu C, Usari T, Laliberte R, Dychter SS, Zhang X, Tabernero J, Kopetz S; BREAKWATER Trial Investigators. Elez E, et al. N Engl J Med. 2025 Jun 26;392(24):2425-2437. doi: 10.1056/NEJMoa2501912. Epub 2025 May 30. N Engl J Med. 2025. PMID: 40444708 Free PMC article. Clinical Trial.
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, Vaishampayan U, Berger R, Sezer A, Alanko T, de Wit R, Li C, Omlin A, Procopio G, Fukasawa S, Tabata KI, Park SH, Feyerabend S, Drake CG, Wu H, Qiu P, Kim J, Poehlein C, de Bono JS. Antonarakis ES, et al. Among authors: alanko t. J Clin Oncol. 2020 Feb 10;38(5):395-405. doi: 10.1200/JCO.19.01638. Epub 2019 Nov 27. J Clin Oncol. 2020. PMID: 31774688 Free PMC article. Clinical Trial.
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators. Shitara K, et al. Lancet. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4. Lancet. 2018. PMID: 29880231 Clinical Trial.
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors.
Jirovec E, Quixabeira DCA, Clubb JHA, Pakola SA, Kudling T, Arias V, Haybout L, Jalkanen K, Alanko T, Monberg T, Khammari A, Dreno B, Svane IM, Block MS, Adamo DA, Mäenpää J, Kistler C, Sorsa S, Hemminki O, Kanerva A, Santos JM, Cervera-Carrascon V, Hemminki A. Jirovec E, et al. Among authors: alanko t. J Exp Clin Cancer Res. 2024 Nov 6;43(1):297. doi: 10.1186/s13046-024-03219-0. J Exp Clin Cancer Res. 2024. PMID: 39506856 Free PMC article. Clinical Trial.
Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial.
Pakola SA, Peltola KJ, Clubb JHA, Jirovec E, Haybout L, Kudling TV, Alanko T, Korpisaari R, Juteau S, Jaakkola M, Sormunen J, Kemppainen J, Hemmes A, Pellinen T, van der Heijden M, Quixabeira DCA, Kistler C, Sorsa S, Havunen R, Santos JM, Cervera-Carrascon V, Hemminki A. Pakola SA, et al. Among authors: alanko t. Clin Cancer Res. 2024 Sep 3;30(17):3715-3725. doi: 10.1158/1078-0432.CCR-23-3874. Clin Cancer Res. 2024. PMID: 38546220 Free PMC article. Clinical Trial.
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.
Block MS, Clubb JHA, Mäenpää J, Pakola S, Quixabeira DCA, Kudling T, Jirovec E, Haybout L, van der Heijden M, Zahraoui S, Grönberg-Vähä-Koskela S, Raatikainen S, Arias V, Basnet S, Ojala N, Pellinen T, Hemmes A, Välimäki K, Pasanen A, Alanko T, Adamo D, Ramadan S, Sormunen J, Kononen J, Cohen JW, Chisamore MJ, Goldfinch J, Sorsa S, Havunen R, Kistler C, Kalervo A, Cervera-Carrascon V, Dos Santos JM, Hemminki A. Block MS, et al. Among authors: alanko t. Nat Commun. 2025 Feb 5;16(1):1381. doi: 10.1038/s41467-025-56482-w. Nat Commun. 2025. PMID: 39910037 Free PMC article. Clinical Trial.
Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.
Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I, Tähtinen S, Oksanen M, Heiskanen R, Pesonen S, Joensuu T, Alanko T, Partanen K, Laasonen L, Kairemo K, Pesonen S, Kangasniemi L, Hemminki A. Kanerva A, et al. Among authors: alanko t. Clin Cancer Res. 2013 May 15;19(10):2734-44. doi: 10.1158/1078-0432.CCR-12-2546. Epub 2013 Mar 14. Clin Cancer Res. 2013. PMID: 23493351 Clinical Trial.
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes.
Kudling TV, Bychkov D, Clubb JHA, Pakola SA, Arias V, Jirovec E, van der Heijden M, Ojala N, Quixabeira DCA, Haybout L, Jalkanen KJ, Alanko T, Havunen R, Sorsa S, Kistler C, Kanerva A, Hemminki O, Santos JM, Cervera-Carrascon V, Hemminki A. Kudling TV, et al. Among authors: alanko t. Cancer Gene Ther. 2025 Jun;32(6):649-661. doi: 10.1038/s41417-025-00901-z. Epub 2025 Apr 10. Cancer Gene Ther. 2025. PMID: 40211048 Free PMC article. Clinical Trial.
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial.
Pakola SA, Clubb JHA, Kudling TV, van der Heijden M, Jirovec E, Arias V, Haybout L, Peltola K, Alanko T, Sormunen J, Pellinen T, Taipale K, Quixabeira DCA, Kistler C, Havunen R, Sorsa S, Santos JM, Cervera-Carrascon V, Hemminki A. Pakola SA, et al. Among authors: alanko t. J Immunother Cancer. 2025 Jan 27;13(1):e010493. doi: 10.1136/jitc-2024-010493. J Immunother Cancer. 2025. PMID: 39870491 Free PMC article. Clinical Trial.
71 results